{"url_path":"/sec/apre/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1781983/0001104659-26-059734-index.html","accession_number":"0001104659-26-059734","cik":"0001781983","ticker":"APRE","issuer_name":"Aprea Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1781983/0001104659-26-059734-index.html","primary_entity_key":"0001781983","primary_entity_name":"Aprea Therapeutics, Inc."},"word_count":117,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits.**\n\n​\n\n(d) Exhibits.\n\n​\n\n​\n\n​\n\n**Exhibit**\n**Number**\n\n**  ​ ​ ​**\n\n**Description**\n\n99.1\n\n​\n\n[Press release issued by Aprea Therapeutics, Inc. dated May 13, 2026.](apre-20260513xex99d1.htm)\n\n99.2\n\n​\n\n[Corporate Presentation (May 2026).](apre-20260513xex99d2.htm)\n\n104\n\n​\n\nCover Page Interactive Data File (embedded within the inline XBRL document).\n\n​\n\n​\n\n​\n\n​\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n**Aprea Therapeutics, Inc.**\n\n​\n\n​\n\nDated: May 13, 2026\n\nBy:\n\n/s/ Oren Gilad\n\n​\n\nName:\n\nOren Gilad, Ph.D.\n\n​\n\nTitle:\n\nPresident and Chief Executive Officer\n\n​\n\n​\n\n​\n\n​"}